Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world filgotinib study tracks arthritis control over 2 years

NCT ID NCT05323591

Disease control Sponsor: Alfasigma S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 155 French adults with moderate-to-severe rheumatoid arthritis who were prescribed filgotinib (Jyseleca) for the first time. Over two years, researchers measured how many patients stayed on the drug and how well it controlled their disease activity. The goal was to see if filgotinib works as well in everyday clinics as it does in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Filgotinib (Jyseleca)
What this could lead to
If successful, this study could confirm that filgotinib works well in everyday practice for controlling rheumatoid arthritis symptoms and slowing joint damage.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not prove filgotinib is better than other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

155 people

The number who actually took part.

Started

May 2022

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of participants aged ≥ 18 years with moderate to severe active RA receiving filgotinib who will be enrolled in France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time. * Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label. * Participants must be willing and able to use an electronic device to complete the study PROs. * Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study. Exclusion Criteria: * Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries. * Female participant is pregnant or intending to become pregnant while taking filgotinib.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • CH de Cahors

    Cahors, 46005, France

  • CHRU de Tours

    Tours, 37044, France

  • CHU Amiens Picardie site Nord

    Amiens, 80054, France

  • CHU Bordeaux

    Bordeaux, 33000, France

  • CHU Toulouse

    Toulouse, 31000, France

  • CHU de Amiens Picardie

    Amiens, 80054, France

  • CHU de Nice

    Nice, 06000, France

  • CHU de Rouen

    Rouen, 76000, France

  • Centre Hospitalier Régional d'Orléans

    Orléans, 45100, France

  • Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne, 42000, France

  • Clinique de l'Infirmerie Protestante de Lyon

    Caluire-et-Cuire, 69300, France

  • Hopital Avicenne AP-HP

    Bobigny, 93000, France

  • Hopital Cochin Service A

    Paris, 75014, France

  • Hopital Robert Debre

    Reims, 51092, France

  • Hopital Roger Salengro

    Lille, 59037, France

  • Hopital Saint Antoine

    Paris, 75012, France

  • Hopital Sud Francilien Corbeil Essonne

    Corbeil-Essonnes, 91106, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.